Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection

NCT03719664 is registered in ClinicalTrials.gov with Frontier Biotechnologies Inc. as lead sponsor.

NCT NCT03719664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03719664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection
Lead sponsor
Frontier Biotechnologies Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 17, 2018
Completion date
December 31, 2022
Enrollment
80 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection